Form 6-K ASTRAZENECA PLC For: Nov 30
Tweet
Share
E-mail
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
30 November 2022 07:05 GMT
AstraZeneca announces sale of its West Chester, Ohio (US)
manufacturing site
National Resilience, Inc. to expand site and support future growth
of its medicines manufacturing capabilities
AstraZeneca today announces the sale of its West Chester site in
Ohio, US, to National Resilience, Inc. (Resilience), a
technology-focused manufacturing company dedicated to broadening
access to complex medicines.
Andrew Wirths, Senior Vice President, Americas Supply Region,
AstraZeneca, said: "As part of our long-term strategy to ensure our
global supply network remains fit for the future, we are
continuously optimising our manufacturing footprint to meet the
evolving needs of our pipeline and portfolio. The transfer of our
West Chester site to Resilience will enable the continued supply of
AstraZeneca medicines to patients, as well as the continued
employment for more than 500 people working at the West Chester
site. I'm encouraged by Resilience's plans to transform the site
into their drug product centre of excellence."
"The West Chester site will play an important role in the delivery
of our mission to broaden access to complex medicines, protect
biopharmaceutical supply chains, and strengthen domestic
preparedness," said Rahul Singhvi, Sc.D, Chief Executive Officer of
Resilience. "I'm confident that West Chester's premier
capabilities, including the talented employees who are joining
Resilience, will help us expand our business in new
directions."
AstraZeneca expects to complete the sale in the first quarter of
2023, with a phased transition of services.
Notes
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
About Resilience
Resilience is a technology-focused biomanufacturing company
dedicated to broadening access to complex medicines. Founded in
2020, the company is building a sustainable network of high-tech,
end-to-end manufacturing solutions to ensure the treatments of
today and tomorrow can be made quickly, safely, and at scale.
Resilience seeks to free its partners to focus on the discoveries
that improve patients' lives by continuously advancing the science
of biopharmaceutical manufacturing and development. For more
information, visit www.Resilience.com and
follow us on social media: @IncResilience on
Twitter and Resilience on
LinkedIn.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
30 November 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
- Relevate Power Announces Rebranding and Launches Equity Raise to Accelerate M&A Growth
- AstraZeneca (AZN) reports FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
